Alembic Pharmaceuticals has announced its Q3FY26 financial results for the quarter ended December 31, 2025, demonstrating robust revenue growth of 11% alongside strong operational performance across all business segments. The pharmaceutical company delivered consistent execution and maintained healthy margins despite recognizing a one-time provision under new labour codes.

Strong Financial Performance in Q3FY26

The company achieved consolidated revenue from operations of ₹1,876 crore compared to ₹1,693 crore in Q3FY25, representing a growth of 11%. EBITDA increased by 14% to ₹308 crore with EBITDA margin maintained at 16% of revenue. Profit Before Exceptional Items and Tax increased by 15% to ₹205 crore, demonstrating strong operational efficiency.

Segment-wise Business Performance

The India Branded Business delivered 6% year-over-year growth, reaching ₹652 crore in revenue for the quarter. Growth was supported by Gynaecology, Ophthalmology and Animal healthcare segments, while the Anti-infective segment grew in line with market performance. The company successfully introduced 4 new products during the quarter.

International Operations Drive Growth

US Generics business grew by 6% to ₹553 crore with 2 launches in the US market during the quarter. The Ex-US International Generics segment demonstrated exceptional performance with 36% growth to ₹406 crore. The company received 7 ANDA approvals during the quarter, bringing cumulative ANDA approvals to 232.

Impact of Labour Code Implementation

Pursuant to changes under the new labour code, the company recognized a one-time provision of ₹42 crore towards employee benefits. This exceptional item impacted the reported Profit After Tax, which stood at ₹133 crore after accounting for this provision.

Management Commentary and Strategic Focus

Commenting on the results, Mr. Pranav Amin, MD of Alembic Pharmaceuticals Limited, highlighted the sustained momentum across businesses supported by consistent execution and continued focus on profitability. The company strengthened its presence in Australia, Canada, Europe, the USA and other key markets. The pre-R&D EBITDA margin remained healthy at 25%, while the company continued investing around 9% of revenue in R&D to build a robust pipeline for future growth.

Nine-Month Performance Overview

For the nine months ended December 31, 2025, total revenue reached ₹5,497 crore compared to ₹4,902 crore in the corresponding period, representing 12% growth. The integration of Utility Therapeutics progressed well, with the company working towards launch of Pivya™ in quarter 4 to expand its footprint in branded drugs in the US.

Alembic Pharmaceuticals has achieved a significant regulatory milestone with the receipt of USFDA final approval for Difluprednate Ophthalmic Emulsion, 0.05%. This approval marks another important step in the company's expansion within the US pharmaceutical market.

Product Details and Market Significance

The approved product serves as a generic equivalent to Durezol Ophthalmic Emulsion, expanding Alembic Pharmaceuticals' presence in the ophthalmic therapeutics segment. Difluprednate is a topical corticosteroid used for treating inflammation and pain associated with ocular surgery.

Regulatory Achievement

This latest USFDA approval brings Alembic Pharmaceuticals' total count of Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug Administration to 233. This milestone demonstrates the company's consistent regulatory compliance and successful navigation of the complex USFDA approval process.

Strategic Impact

The approval strengthens Alembic Pharmaceuticals' generic drug portfolio in the United States market. With 233 ANDA approvals now in its portfolio, the company continues to build its presence across various therapeutic segments, including the specialized ophthalmic market segment.